Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 10 of 10 entries
Sorted by: Best Match Show Resources per page
Executive functioning and quality of life in acromegaly.

Psychology research and behavior management

Solomon E, Brănișteanu D, Dumbravă A, Solomon RG, Kiss L, Glod M, Preda C.
PMID: 30655710
Psychol Res Behav Manag. 2019 Jan 03;12:39-44. doi: 10.2147/PRBM.S183950. eCollection 2019.

INTRODUCTION: Active acromegaly is a rare chronic endocrine disorder caused by excessive growth hormone (GH). Clinical studies suggest that cognitive performance is impaired in acromegaly - particularly executive function as well as short- and long-term memory. This study compared...

Cite
Solomon E, Brănișteanu D, Dumbravă A, et al. Executive functioning and quality of life in acromegaly. Psychol Res Behav Manag. 2019;12:39-44doi: 10.2147/PRBM.S183950.
Solomon, E., Brănișteanu, D., Dumbravă, A., Solomon, R. G., Kiss, L., Glod, M., & Preda, C. (2019). Executive functioning and quality of life in acromegaly. Psychology research and behavior management, 1239-44. https://doi.org/10.2147/PRBM.S183950
Solomon, Emilia, et al. "Executive functioning and quality of life in acromegaly." Psychology research and behavior management vol. 12 (2019): 39-44. doi: https://doi.org/10.2147/PRBM.S183950
Solomon E, Brănișteanu D, Dumbravă A, Solomon RG, Kiss L, Glod M, Preda C. Executive functioning and quality of life in acromegaly. Psychol Res Behav Manag. 2019 Jan 03;12:39-44. doi: 10.2147/PRBM.S183950. eCollection 2019. PMID: 30655710; PMCID: PMC6322494.
Copy Download .nbib Format: NLM
The impact of growth hormone replacement therapy on adipokines, but not upon Ghrelin.

Minerva endocrinology

Belceanu AD, Bilha SC, Vulpoi C, Branisteanu DD.
PMID: 34546018
Minerva Endocrinol (Torino). 2021 Sep 21; doi: 10.23736/S2724-6507.21.03588-0. Epub 2021 Sep 21.

BACKGROUND: Besides growth acceleration, growth hormone (GH) therapy of GH deficient (GHD) children improves body composition by decreasing body fat. This effect is due to GH interaction with lipid and carbohydrate metabolism, possibly also mediated by adipokines secreted by...

Cite
Belceanu AD, Bilha SC, Vulpoi C, et al. The impact of growth hormone replacement therapy on adipokines, but not upon Ghrelin. Minerva Endocrinol (Torino). 2021;doi: 10.23736/S2724-6507.21.03588-0.
Belceanu, A. D., Bilha, S. C., Vulpoi, C., & Branisteanu, D. D. (2021). The impact of growth hormone replacement therapy on adipokines, but not upon Ghrelin. Minerva endocrinology, . https://doi.org/10.23736/S2724-6507.21.03588-0
Belceanu, Alina D, et al. "The impact of growth hormone replacement therapy on adipokines, but not upon Ghrelin." Minerva endocrinology vol. (2021). doi: https://doi.org/10.23736/S2724-6507.21.03588-0
Belceanu AD, Bilha SC, Vulpoi C, Branisteanu DD. The impact of growth hormone replacement therapy on adipokines, but not upon Ghrelin. Minerva Endocrinol (Torino). 2021 Sep 21; doi: 10.23736/S2724-6507.21.03588-0. Epub 2021 Sep 21. PMID: 34546018.
Copy Download .nbib Format: NLM
Drug-induced Rowell syndrome, a rare and difficult to manage disease: A case report.

Experimental and therapeutic medicine

Brănișteanu DE, Ianoşi SL, Dimitriu A, Stoleriu G, Oanţǎ A, Brănișteanu DC.
PMID: 29434682
Exp Ther Med. 2018 Jan;15(1):785-788. doi: 10.3892/etm.2017.5557. Epub 2017 Nov 23.

Rowell syndrome is defined as the association between lupus erythematosus, erythema multiforme-like lesions and characteristic immunological changes including positive tests for rheumatoid factor, speckled antinuclear antibody, positive anti-Ro or anti-La antibodies. The present report presents the case of a...

Cite
Brănișteanu DE, Ianoşi SL, Dimitriu A, et al. Drug-induced Rowell syndrome, a rare and difficult to manage disease: A case report. Exp Ther Med. 2017;15(1):785-788doi: 10.3892/etm.2017.5557.
Brănișteanu, D. E., Ianoşi, S. L., Dimitriu, A., Stoleriu, G., Oanţǎ, A., & Brănișteanu, D. C. (2018). Drug-induced Rowell syndrome, a rare and difficult to manage disease: A case report. Experimental and therapeutic medicine, 15(1), 785-788. https://doi.org/10.3892/etm.2017.5557
Brănișteanu, Daciana Elena, et al. "Drug-induced Rowell syndrome, a rare and difficult to manage disease: A case report." Experimental and therapeutic medicine vol. 15,1 (2018): 785-788. doi: https://doi.org/10.3892/etm.2017.5557
Brănișteanu DE, Ianoşi SL, Dimitriu A, Stoleriu G, Oanţǎ A, Brănișteanu DC. Drug-induced Rowell syndrome, a rare and difficult to manage disease: A case report. Exp Ther Med. 2018 Jan;15(1):785-788. doi: 10.3892/etm.2017.5557. Epub 2017 Nov 23. PMID: 29434682; PMCID: PMC5777104.
Copy Download .nbib Format: NLM
Bone mineral density predictors in long-standing type 1 and type 2 diabetes mellitus.

BMC endocrine disorders

Bilha SC, Leustean L, Preda C, Branisteanu DD, Mihalache L, Ungureanu MC.
PMID: 34362364
BMC Endocr Disord. 2021 Aug 06;21(1):156. doi: 10.1186/s12902-021-00815-5.

BACKGROUND: Despite the increased fracture risk, bone mineral density (BMD) is variable in type 1 (T1D) and type 2 (T2D) diabetes mellitus. We aimed at comparing independent BMD predictors in T1D, T2D and control subjects, respectively.METHODS: Cross-sectional case-control study...

Cite
Bilha SC, Leustean L, Preda C, et al. Bone mineral density predictors in long-standing type 1 and type 2 diabetes mellitus. BMC Endocr Disord. 2021;21(1):156doi: 10.1186/s12902-021-00815-5.
Bilha, S. C., Leustean, L., Preda, C., Branisteanu, D. D., Mihalache, L., & Ungureanu, M. C. (2021). Bone mineral density predictors in long-standing type 1 and type 2 diabetes mellitus. BMC endocrine disorders, 21(1), 156. https://doi.org/10.1186/s12902-021-00815-5
Bilha, Stefana Catalina, et al. "Bone mineral density predictors in long-standing type 1 and type 2 diabetes mellitus." BMC endocrine disorders vol. 21,1 (2021): 156. doi: https://doi.org/10.1186/s12902-021-00815-5
Bilha SC, Leustean L, Preda C, Branisteanu DD, Mihalache L, Ungureanu MC. Bone mineral density predictors in long-standing type 1 and type 2 diabetes mellitus. BMC Endocr Disord. 2021 Aug 06;21(1):156. doi: 10.1186/s12902-021-00815-5. PMID: 34362364; PMCID: PMC8344168.
Copy Download .nbib Format: NLM
New insights into the metabolic-bone crosstalk in active acromegaly.

Endokrynologia Polska

Bilha SC, Matei A, Constantinescu D, Pavel Tanasa M, Mogos-Cioncu R, Cianga P, Preda C, Branisteanu DD.
PMID: 33749810
Endokrynol Pol. 2021;72(3):201-210. doi: 10.5603/EP.a2021.0028. Epub 2021 Mar 22.

INTRODUCTION: Body composition (BC) and adipokines share bone active properties and display an altered profile in acromegaly. The fibroblast growth factor 23 (FGF23)/α-Klotho system, also involved in bone metabolism, is upregulated in growth hormone (GH) excess states. Hence, we...

Cite
Bilha SC, Matei A, Constantinescu D, et al. New insights into the metabolic-bone crosstalk in active acromegaly. Endokrynol Pol. 2021;72(3):201-210doi: 10.5603/EP.a2021.0028.
Bilha, S. C., Matei, A., Constantinescu, D., Pavel Tanasa, M., Mogos-Cioncu, R., Cianga, P., Preda, C., & Branisteanu, D. D. (2021). New insights into the metabolic-bone crosstalk in active acromegaly. Endokrynologia Polska, 72(3), 201-210. https://doi.org/10.5603/EP.a2021.0028
Bilha, Stefana Catalina, et al. "New insights into the metabolic-bone crosstalk in active acromegaly." Endokrynologia Polska vol. 72,3 (2021): 201-210. doi: https://doi.org/10.5603/EP.a2021.0028
Bilha SC, Matei A, Constantinescu D, Pavel Tanasa M, Mogos-Cioncu R, Cianga P, Preda C, Branisteanu DD. New insights into the metabolic-bone crosstalk in active acromegaly. Endokrynol Pol. 2021;72(3):201-210. doi: 10.5603/EP.a2021.0028. Epub 2021 Mar 22. PMID: 33749810.
Copy Download .nbib Format: NLM
Current diagnosis and management strategies in pachychoroid spectrum of diseases (Review).

Experimental and therapeutic medicine

Moraru AD, Costin D, Moraru RL, Costuleanu M, Brănișteanu DC.
PMID: 32905090
Exp Ther Med. 2020 Oct;20(4):3528-3535. doi: 10.3892/etm.2020.9094. Epub 2020 Aug 04.

This review presents a systematic analysis of the literature regarding the pachychoroid disease spectrum nomenclature, diagnosis criteria and therapeutic options. Pachychoroid related diseases are a new concept, introduced into the ophthalmological nomenclature in 2013 and evolving both as concept...

Cite
Moraru AD, Costin D, Moraru RL, et al. Current diagnosis and management strategies in pachychoroid spectrum of diseases (Review). Exp Ther Med. 2020;20(4):3528-3535doi: 10.3892/etm.2020.9094.
Moraru, A. D., Costin, D., Moraru, R. L., Costuleanu, M., & Brănișteanu, D. C. (2020). Current diagnosis and management strategies in pachychoroid spectrum of diseases (Review). Experimental and therapeutic medicine, 20(4), 3528-3535. https://doi.org/10.3892/etm.2020.9094
Moraru, Andreea Dana, et al. "Current diagnosis and management strategies in pachychoroid spectrum of diseases (Review)." Experimental and therapeutic medicine vol. 20,4 (2020): 3528-3535. doi: https://doi.org/10.3892/etm.2020.9094
Moraru AD, Costin D, Moraru RL, Costuleanu M, Brănișteanu DC. Current diagnosis and management strategies in pachychoroid spectrum of diseases (Review). Exp Ther Med. 2020 Oct;20(4):3528-3535. doi: 10.3892/etm.2020.9094. Epub 2020 Aug 04. PMID: 32905090; PMCID: PMC7464929.
Copy Download .nbib Format: NLM
Assessment of dermal papillary and microvascular parameters in psoriasis vulgaris using .

Experimental and therapeutic medicine

Batani A, Brănișteanu DE, Ilie MA, Boda D, Ianosi S, Ianosi G, Caruntu C.
PMID: 29434710
Exp Ther Med. 2018 Feb;15(2):1241-1246. doi: 10.3892/etm.2017.5542. Epub 2017 Nov 22.

No abstract available.

Cite
Batani A, Brănișteanu DE, Ilie MA, et al. Assessment of dermal papillary and microvascular parameters in psoriasis vulgaris using . Exp Ther Med. 2017;15(2):1241-1246doi: 10.3892/etm.2017.5542.
Batani, A., Brănișteanu, D. E., Ilie, M. A., Boda, D., Ianosi, S., Ianosi, G., & Caruntu, C. (2018). Assessment of dermal papillary and microvascular parameters in psoriasis vulgaris using . Experimental and therapeutic medicine, 15(2), 1241-1246. https://doi.org/10.3892/etm.2017.5542
Batani, Alexandra, et al. "Assessment of dermal papillary and microvascular parameters in psoriasis vulgaris using ." Experimental and therapeutic medicine vol. 15,2 (2018): 1241-1246. doi: https://doi.org/10.3892/etm.2017.5542
Batani A, Brănișteanu DE, Ilie MA, Boda D, Ianosi S, Ianosi G, Caruntu C. Assessment of dermal papillary and microvascular parameters in psoriasis vulgaris using . Exp Ther Med. 2018 Feb;15(2):1241-1246. doi: 10.3892/etm.2017.5542. Epub 2017 Nov 22. PMID: 29434710; PMCID: PMC5774437.
Copy Download .nbib Format: NLM
Role of copeptin in the diagnosis of traumatic neuroendocrine dysfunction.

Neuropeptides

Săcărescu A, Turliuc MD, Brănișteanu DD.
PMID: 34175655
Neuropeptides. 2021 Oct;89:102167. doi: 10.1016/j.npep.2021.102167. Epub 2021 Jun 24.

Traumatic neuroendocrine dysfunction may present with diabetes insipidus (DI) or with the syndrome of inappropriate antidiuretic hormone secretion (SIADH). Both these pathologies involve a disturbance in the antidiuretic hormone (ADH) secretion, causing dysnatremias. Diagnosis of posttraumatic ADH dysfunction is...

Cite
Săcărescu A, Turliuc MD, Brănișteanu DD. Role of copeptin in the diagnosis of traumatic neuroendocrine dysfunction. Neuropeptides. 2021;89:102167doi: 10.1016/j.npep.2021.102167.
Săcărescu, A., Turliuc, M. D., & Brănișteanu, D. D. (2021). Role of copeptin in the diagnosis of traumatic neuroendocrine dysfunction. Neuropeptides, 89102167. https://doi.org/10.1016/j.npep.2021.102167
Săcărescu, Alina, et al. "Role of copeptin in the diagnosis of traumatic neuroendocrine dysfunction." Neuropeptides vol. 89 (2021): 102167. doi: https://doi.org/10.1016/j.npep.2021.102167
Săcărescu A, Turliuc MD, Brănișteanu DD. Role of copeptin in the diagnosis of traumatic neuroendocrine dysfunction. Neuropeptides. 2021 Oct;89:102167. doi: 10.1016/j.npep.2021.102167. Epub 2021 Jun 24. PMID: 34175655.
Copy Download .nbib Format: NLM
Body composition, adipokines, FGF23-Klotho and bone in kidney transplantation: Is there a link?.

Journal of nephrology

Matei A, Bilha SC, Constantinescu D, Pavel-Tanasa M, Cianga P, Covic A, Branisteanu DD.
PMID: 33560479
J Nephrol. 2021 Feb 09; doi: 10.1007/s40620-021-00972-9. Epub 2021 Feb 09.

BACKGROUND: Kidney transplantation-associated mineral and bone disorder (KT-MBD) still represents a black box on the long-term due to scarce available data. We aimed to investigate the impact of non-classical bone regulating factors (body composition, adipokines, inflammatory markers, fibroblast growth...

Cite
Matei A, Bilha SC, Constantinescu D, et al. Body composition, adipokines, FGF23-Klotho and bone in kidney transplantation: Is there a link?. J Nephrol. 2021;doi: 10.1007/s40620-021-00972-9.
Matei, A., Bilha, S. C., Constantinescu, D., Pavel-Tanasa, M., Cianga, P., Covic, A., & Branisteanu, D. D. (2021). Body composition, adipokines, FGF23-Klotho and bone in kidney transplantation: Is there a link?. Journal of nephrology, . https://doi.org/10.1007/s40620-021-00972-9
Matei, Anca, et al. "Body composition, adipokines, FGF23-Klotho and bone in kidney transplantation: Is there a link?." Journal of nephrology vol. (2021). doi: https://doi.org/10.1007/s40620-021-00972-9
Matei A, Bilha SC, Constantinescu D, Pavel-Tanasa M, Cianga P, Covic A, Branisteanu DD. Body composition, adipokines, FGF23-Klotho and bone in kidney transplantation: Is there a link?. J Nephrol. 2021 Feb 09; doi: 10.1007/s40620-021-00972-9. Epub 2021 Feb 09. PMID: 33560479.
Copy Download .nbib Format: NLM
Immunohistochemical study of CD117 in various cutaneous melanocytic lesions.

Experimental and therapeutic medicine

Radu A, Bejenaru C, Ţolea I, Maranduca MA, Brănişteanu DC, Bejenaru LE, Petrariu FD, Stoleriu G, Brănişteanu DE.
PMID: 33363589
Exp Ther Med. 2021 Jan;21(1):78. doi: 10.3892/etm.2020.9510. Epub 2020 Nov 26.

The aim of the present study was to carried out a comparative immunohistochemical evaluation of CD117 (c-Kit), a biomarker that evaluates both tumor progression and prognosis, in different melanocytic lesions, to emphasize the significance of this biomarker in malignant...

Cite
Radu A, Bejenaru C, Ţolea I, et al. Immunohistochemical study of CD117 in various cutaneous melanocytic lesions. Exp Ther Med. 2020;21(1):78doi: 10.3892/etm.2020.9510.
Radu, A., Bejenaru, C., Ţolea, I., Maranduca, M. A., Brănişteanu, D. C., Bejenaru, L. E., Petrariu, F. D., Stoleriu, G., & Brănişteanu, D. E. (2021). Immunohistochemical study of CD117 in various cutaneous melanocytic lesions. Experimental and therapeutic medicine, 21(1), 78. https://doi.org/10.3892/etm.2020.9510
Radu, Antonia, et al. "Immunohistochemical study of CD117 in various cutaneous melanocytic lesions." Experimental and therapeutic medicine vol. 21,1 (2021): 78. doi: https://doi.org/10.3892/etm.2020.9510
Radu A, Bejenaru C, Ţolea I, Maranduca MA, Brănişteanu DC, Bejenaru LE, Petrariu FD, Stoleriu G, Brănişteanu DE. Immunohistochemical study of CD117 in various cutaneous melanocytic lesions. Exp Ther Med. 2021 Jan;21(1):78. doi: 10.3892/etm.2020.9510. Epub 2020 Nov 26. PMID: 33363589; PMCID: PMC7725021.
Copy Download .nbib Format: NLM
Showing 1 to 10 of 10 entries